# hVIVO signs £5.2m contract with a global biotechnology company

- Link: https://www.directorstalkinterviews.com/hvivo%c2%a0signs-5.2m-contract-with-a-global-biotechnology-company/4121096101
- Published: 2023-01-04T07:08:33+00:00
- Author: Giles

**[hVIVO plc](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l)**(
[LON:HVO](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l)) (formerly
Open Orphan plc), a rapidly growing specialist contract research organisation (CRO)
and world leader in testing infectious and respiratory disease products using human
challenge clinical trials, has announced that it has signed a £5.2m contract with
a global biotechnology company headquartered in Asia Pacific to test their respiratory
syncytial virus vaccine candidate, using hVIVO’s established RSV Human Challenge
Study Model. The Company also announces that it will provide a trading update for
the year ended 31 December 2022 on 25 January 2023.

The Phase 2a double-blinded placebo-controlled human challenge trial will take place
at the Company’s specialist quarantine facilities in London and will evaluate the
safety, immunogenicity and efficacy of the client’s vaccine candidate against RSV
infection. The study is expected to commence in H2 2023, with the revenue being 
recognised across 2023 and 2024. As part of the study, hVIVO will recruit healthy
volunteers via the Company’s dedicated volunteer recruitment arm, FluCamp.

This is the first human challenge trial contract that hVIVO has signed with a client
in the Asia-Pacific (“APAC”) region in over a decade, and is a growth area for the
Company as it seeks to further diversify its client base and orderbook. The contract
also further highlights the growing demand for challenge trials from global biopharmaceutical
companies as they seek to gain cost-effective efficacy data to de-risk their development
programmes and enhance their candidate’s value before commencing later-stage field
studies.

hVIVO has three decades of experience and expertise in safely conducting challenge
studies across a range of respiratory viruses, including various strains of influenza,
respiratory syncytial virus (RSV) and human rhinovirus (HRV – common cold virus),
and asthma, as well as malaria.

> **Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said:** _“I am delighted 
> to have signed this contract with a biotechnology company headquartered in Asia
> Pacific to test its RSV vaccine candidate, which is our first contract signed 
> in the region in over a decade. APAC has been identified as a key growth region
> for the Company, and this contract is an encouraging indicator that our strategy
> there is bearing fruit. I am optimistic that more biopharma companies in the APAC
> region will increasingly recognise both the value of human challenge trials, and
> hVIVO’s reputation as the ‘go-to’ partner in the market._
> _“This award further strengthens our revenue visibility into 2024 and gives weight
> to the fact that we have a strong and sustainable growth model. The team has worked
> hard to achieve record numbers in 2022, and this award is the perfect start to
> 2023.”  _

> **Dr Andrew Catchpole, Chief Scientific Officer of hVIVO said:** _“Although RSV
> has a low chance of causing serious illness in healthy adults, it can be highly
> virulent for children and the elderly. The disease has caused particular strain
> on paediatric health this winter in the US and Europe, with reports suggesting
> newborns are being hospitalised in the US at seven times the rate observed in 
> 2018, the last non-COVID-19 winter season^(1). This has reinforced the global 
> need for innovative vaccines and antivirals; the hVIVO RSV Human Challenge Model
> can play a critical role in bringing these treatments to market more quickly.”_

_1._ CNBC News, 18 November 2022: Children’s hospitals call on Biden to declare 
emergency in response to ‘unprecedented’ RSV surge

Share on:
